Want to see PLX full AI Analyst Report?
Top Page
Protalix
(NYSE MKT:PLX)
Select Model
Select Model
Rating:68Neutral
Price Target:
$2.50
▲(5.49% Upside)
Action:Reiterated
Date:06/26/26
The score is driven primarily by improving financial performance (higher TTM growth/margins, positive FCF, low leverage) and a solid earnings call with reaffirmed guidance and strong liquidity. Technicals are moderately supportive but not fully strong over longer horizons, while valuation looks reasonable but is tempered by milestone-influenced earnings and limited yield support.
Positive Factors
ProCellEx platform & manufacturing
Protalix’s proprietary plant cell–based ProCellEx platform and in-house manufacturing that already supports marketed products create a durable competitive advantage. Owning production enables supply control, lower incremental costs for follow-on biologics, and makes the company an attractive partner for licensing and profit-share deals.
Negative Factors
Lumpy cash flow history
Historical volatility in operating and free cash flow highlights dependence on episodic events (e.g., milestones) and timing of partner purchases. This lumpiness reduces visibility on the company’s ability to consistently fund programs and operations without recurring external payments or capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
ProCellEx platform & manufacturing
Protalix’s proprietary plant cell–based ProCellEx platform and in-house manufacturing that already supports marketed products create a durable competitive advantage. Owning production enables supply control, lower incremental costs for follow-on biologics, and makes the company an attractive partner for licensing and profit-share deals.
Read all positive factors
Protalix (PLX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$190.15M
Dividend YieldN/A
Average Volume (3M)607.22K
Price to Earnings (P/E)9.2
Beta (1Y)0.67
Revenue Growth30.14%
EPS Growth181.54%
CountryUS
Employees226
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.24
Shares Outstanding80,571,640
10 Day Avg. Volume513,750
30 Day Avg. Volume607,216
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.93
Price to Sales (P/S)2.68
P/FCF Ratio-10.37
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$12.00Price Target Upside406.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.2
Revenue Forecast (FY)$78.30M
Protalix Business Overview & Revenue Model
Company Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides ...
How the Company Makes Money
Protalix makes money primarily through a combination of (a) product-related economics on commercialized therapies and (b) collaboration/partnering revenue tied to development and commercialization of its biologics. These revenue streams typically ...
Protalix Earnings Call Summary
Earnings Call Date:Aug 12, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call presented several strong operational and financial positives — double-digit quarterly revenue growth, a >100% year-to-date revenue increase, meaningful Q2 net income, strong Elfabrio commercial momentum with regulatory and patent tailwinds, a solid cash position and advancing pipeline (PRX-115 with topline expected H2 2027). Offsetting risks include quarter-to-quarter revenue lumpiness and partner concentration (Chiesi), a reliance on a one-time $25M milestone in H1, increased cost of revenues and taxes, and clinical uncertainties around immunogenicity and regimen selection for PRX-115. Overall, the positives — particularly the robust revenue growth, improved profitability and cash position — outweigh the noted risks, though sustainability and immunogenicity remain items to monitor.Positive Updates
Quarterly Revenue Growth
Total revenues for Q2 2026 were $19.9M versus $15.7M in Q2 2025, an increase of $4.2M (+26.8%).
Negative Updates
Quarter-to-Quarter Revenue Variability and Partner Concentration
Revenues can be lumpy due to timing of shipments and partner inventory management (Chiesi purchases described as uneven), indicating concentration risk and quarter-to-quarter volatility in reported sales.
Read all updates
Q2-2026 Updates
Positive
Negative
Quarterly Revenue Growth
Total revenues for Q2 2026 were $19.9M versus $15.7M in Q2 2025, an increase of $4.2M (+26.8%).
Read all positive updates
Company Guidance
The company reiterated that it remains on track to meet full‑year 2026 revenue guidance after reporting Q2 2026 total revenues of $19.9M (up from $15.7M YoY) and H1 2026 revenues of $53.6M (vs. $25.8M), driven largely by Elfabrio sales through Chiesi and a previously‑reported $25M Chiesi milestone recognized in Q1; Q2 revenues from selling goods were $19.8M (vs. $15.4M), cost of revenues rose to $7.8M (from $5.9M), R&D expenses fell to $4.4M (from $6.0M) largely due to a $2.1M R&D law benefit that will be available ongoing, G&A was $3.1M (up $0.5M), finance income net was $0.2M (vs. financial expenses of $0.5M), taxes were $1.1M (vs. $0.5M), and net income was $3.8M or $0.05 per share (vs. $0.16M); the balance sheet shows $40.7M in cash, cash equivalents and short‑term deposits, with no outstanding debt or warrants, and management highlighted that Elfabrio is positioned to capture 15–20% of a global Fabry market projected to reach ~$3.2B by 2031 (supported by recent E4W European approval), while PRX‑115 enrollment is expected to complete by year‑end with top‑line RELEASE results anticipated in H2 2027.Protalix Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 80.62M | 52.74M | 53.40M | 65.49M | 47.64M | 38.35M |
| Gross Profit | 55.79M | 25.24M | 29.08M | 42.51M | 28.05M | 22.00M |
| EBITDA | 26.28M | -2.95M | 6.52M | 12.94M | -10.78M | -18.94M |
| Net Income | 18.95M | -6.60M | 2.93M | 8.31M | -14.93M | -27.58M |
Balance Sheet | ||||||
| Total Assets | 110.34M | 82.35M | 73.42M | 84.43M | 55.79M | 73.67M |
| Cash, Cash Equivalents and Short-Term Investments | 27.42M | 30.27M | 34.83M | 44.56M | 22.18M | 38.98M |
| Total Debt | 9.21M | 8.32M | 5.53M | 27.69M | 33.47M | 33.47M |
| Total Liabilities | 38.93M | 34.12M | 30.21M | 50.87M | 66.43M | 79.70M |
| Stockholders Equity | 71.40M | 48.23M | 43.21M | 33.57M | -10.64M | -6.04M |
Cash Flow | ||||||
| Free Cash Flow | 7.67M | -13.63M | 7.39M | -2.47M | -25.63M | -11.74M |
| Operating Cash Flow | 9.92M | -11.99M | 8.67M | -1.32M | -25.00M | -10.29M |
| Investing Cash Flow | -1.03M | -2.37M | 4.22M | -16.71M | -5.04M | 18.92M |
| Financing Cash Flow | 296.00K | 9.33M | -16.79M | 24.67M | 8.24M | 12.08M |
Protalix Technical Analysis
Negative
2.37
Price Trends
2.28
Negative
2.20
Positive
2.22
Negative
Market Momentum
0.03
Positive
42.19
Neutral
35.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLX, the sentiment is Negative. The current price of 2.37 is below the 20-day moving average (MA) of 2.38, above the 50-day MA of 2.28, and above the 200-day MA of 2.22, indicating a bearish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 42.19 is Neutral, neither overbought nor oversold. The STOCH value of 35.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PLX.
Protalix Risk Analysis
Protalix disclosed 64 risk factors in its most recent earnings report. Protalix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Protalix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $190.15M | 9.21 | 28.10% | ― | 30.14% | 181.54% | |
67 Neutral | $1.63B | -16.74 | -94.82% | ― | ― | 35.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $238.26M | -3.38 | 593.93% | ― | -77.09% | 6.91% | |
47 Neutral | $2.50B | -60.48 | -35.91% | ― | ― | 35.38% | |
47 Neutral | $232.84M | -2.92 | -41.72% | ― | ― | 17.06% | |
46 Neutral | $176.13M | -1.18 | -181.73% | ― | -64.32% | 25.83% |
* Healthcare Sector Average
PLX
Protalix
2.22
0.74
50.00%
CHRS
Coherus Biosciences
1.20
0.15
14.29%
SLS
SELLAS Life Sciences Group
12.78
11.15
684.05%
TARA
Protara Therapeutics
3.97
0.94
31.02%
FBRX
Forte Biosciences
76.83
65.26
564.04%
IPHA
Innate Pharma
2.18
>-0.01
-0.46%
Protalix Corporate Events
Executive/Board ChangesShareholder Meetings
Protalix Shareholders Approve Directors, Compensation and Incentive Plan
Positive
Jun 25, 2026
Protalix BioTherapeutics held its 2026 Annual Meeting of Stockholders on June 25, 2026, in Tel Aviv, where shareholders elected eight director nominees to the board and approved, on an advisory basis, the compensation packages for the company̵...
Business Operations and StrategyProduct-Related Announcements
Protalix Highlights Elfabrio Dosing Approvals and Growth Plans
Positive
May 21, 2026
On May 21, 2026, Protalix BioTherapeutics posted a new corporate presentation outlining recent regulatory and commercial progress, including a $25 million milestone payment from partner Chiesi. The company highlighted European Commission and U.K. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.